Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
INNOVAX®-ILT
EN
HVT ILT
No
-
Person:Dr Marielle Van HultenDirector of Biology Discovery, EU Geohead PoultryIntervet International BV Wim de Korverstraat 35 Boxmeer the NetherlandsBoxmeer,
, Netherlands (Kingdom of the)Phone: +31485587172,Fax:Email: marielle.vanhulten@merck.com,Website:Related OrganizationMSD Animal Health ()Intervet International BV Wim de Korverstraat 35 Boxmeer the NetherlandsBoxmeer,
, Netherlands (Kingdom of the)Phone: +31485587172,Fax:Email: marielle.vanhulten@merck.com,Website:
Innovax® ILT is a live recombinant vaccine containing Herpesvirus Turkey (HVT) strain FC-126 expressing glycoproteins D and I (gD and gI) from Infectious Laryngotracheitis virus (ILT) strain USDA Challenge Lot No. 83-2. HVT virus induces immunity against Marek’s Disease (MD), and gD and gI from ILT virus induce immunity against ILT virus. Thus, the recombinant viral vaccine Innovax® ILT gives protection against both Marek’s and ILT disease.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-105225-3 Organism Meleagrid alphaherpesvirus 1 (Turkey herpesvirus, Meleagrid herpesvirus 1)Viruses
Meleagrid herpesvirus 1 strain FC-126
EN
EN
- Other (Recombination)
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-114983-1 Glycoprotein D | Gallid alphaherpesvirus 1 (ILTV)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-GENE-SCBD-114984-1 Glycoprotein I | Gallid alphaherpesvirus 1 (ILTV)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
Information regarding the genetic construction the recombinant virus has not been provided.
EN
EN
- Vaccine
EN
EN
| Record type | Field | Record(s) | |
|---|---|---|---|
| Country's Decision or any other Communication | LMO identification | 2 | |
| Risk Assessment generated by a regulatory process | Living modified organism(s) | 2 | |
